{
    "root": "5008a4ec-08c5-4d06-bac9-e7239620a07d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lubiprostone",
    "value": "20250122",
    "ingredients": [
        {
            "name": "LUBIPROSTONE",
            "code": "7662KG2R6K"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "SORBITOL SOLUTION",
            "code": "8KW3E207O2"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        }
    ],
    "indications": "Lubiprostone capsules is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. (1.1) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. (1.2) o Limitations of Use: Effectiveness of lubiprostone capsules in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. (1.2, 7.1) irritable bowel syndrome with constipation (IBS-C) in women ≥18 years old. (1.3)",
    "contraindications": "Recommended Dosage (2.1) CIC and OIC: 24 mcg twice daily. IBS-C: 8 mcg twice daily. See full prescribing information for dosage adjustment by indication and degree of hepatic impairment. Administration Instructions (2.2) Swallow capsules whole and do not break apart or chew, Take capsules with food and water, Assess periodically the need for continuous therapy.",
    "warningsAndPrecautions": "Lubiprostone capsules are available as:\n                  \n                     The 8 mcg lubiprostone capsules are light orange oval capsules containing clear liquid printed with '8' with black ink.Bottles of 60   NDC 31722-403-60\n                  \n                     The 24 mcg lubiprostone capsules are clear orange oval capsules containing clear liquid printed with '24' with black ink.Bottles of 60   NDC 31722-404-60\n                  \n                     Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Protect from light and extreme temperatures.",
    "adverseReactions": "Lubiprostone capsules are contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see Warnings and Precautions (5.5)]."
}